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. In the last decade, cancer drug targets have been extended to signaling pathways, protein-protein complexes, and signaling networks in tumor cells, tumor stromal tissues, and immune systems 2, 3 . In this special column, serval invited researchers with diverse expertise in targeted cancer therapy reviewed recent developments with the goal to facilitate the process from the target discovery to drug development and to clinical applications. This special column contains seven review papers and four original research papers, representing a comprehensive coverage for recent advances of targeted cancer therapy.
In the review paper section, Dr. Liu 4 summarized the current understanding of HER3 receptor biology in various types of cancers and presented strong rationales that therapeutic inactivation of HER3 and/or its downstream signaling could overcome drug resistance and improve the outcomes of cancer patients. Taxanes are first-line anticancer drugs for a number of cancers, including castrationresistant prostate cancer (CRPC). However, the prolonged use of taxanes often leads to multidrug resistance and thus limits their clinical efficacy. Dr. Chen 5 reviewed the recent development of p38 MAPK signaling integration with its specific phosphatase PTPH1 in Kras oncogenesis and their effects on human colon and breast cancer growth through their individual and common targets. Dr. Li 6 summarized recent advances in elucidating resistant mechanisms to taxanes and discussed potential therapeutic strategies for improved treatment of CRPC. The paper from Dr. Wang's group 7 summarized recent development of targeting mutated oncogenic proteins in lung cancer and discussed about the future of personalized medicine in lung cancer. The review from Drs. Zhang and Wu's group 8 highlighted recent developments and the application of CAR-T cell therapy in different hematological malignancies, and suggested potential directions for future improvement on the effectiveness of these adoptive cell therapies. Finally, Dr. Huang 9 reviewed recent developments in the mitogen-activated protein kinase (MAPK) signaling in cancer and summarized progresses made on the development of small molecule inhibitors targeting the MAPK pathway. In particular, this review highlighted the importance and advantages of developing ERK inhibitors to overcome resistance to current inhibitors that target the upstream elements in the MAPK pathway.
In the research paper section, we included several papers using diverse strategies to overcome therapeutic drug resistance. The overexpression of several ATP-binding cassette (ABC) transporters is a well-recognized multidrug resistance mechanism, and proper drug combinations can overcome these resistance. Towards this direction, Dr. Fu's laboratory 10 found olmutinib, an epidermal growth factor receptor tyrosine kinase inhibitor, can significantly increase the drug retention and therapeutic efficacy of several chemotherapeutic drugs in ABCG2-overexpressed cancer cells. This finding encourages further clinical evaluation on the combination of olmutinib with traditional chemotherapy in ABCG2-overexpressing cancer patients. Drs. So and Tipoe 11 reported that a garlic-derived compound S-allylmercaptocysteine (SAMC) targets the low-density lipoprotein receptor-related protein 6 (LRP6), which is frequently over-expressed in tumor tissues of human hepatocellular carcinoma (HCC). Their studies suggested that LPR6 could be a potential drug target of HCC, and that SAMC is promising therapeutic agent for treating certain HCC subtypes. Photothermal therapy (PTT) is a clinically used strategy for cancer treatments, and enhancing the heat-sensitivity of tumor cells can provide a solution to maintaining the therapeutic efficacy of PTT. Towards this goal, Dr. Qian's laboratory 12 reported that gold nanorods together with HSP inhibitor VER-15508 micelles can attenuate the heat-resistance of tumor cells and enhance the therapeutic outcome of mild-temperature photothermal therapy. Finally, Dr. Yallapu 13 reported that a polymer/paclitaxel selfassembly (PTX-SA) formulation show improvement in paclitaxel delivery to cancer cells, potentially enhancing the therapeutic efficacy of paclitaxel in breast cancer.
